Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
Drug: Cabozantinib Drug: Pembrolizumab
Cervical Cancer|Recurrent Cervical Cancer|Metastatic Cervical Cancer|Persistent Cervical Cancer
DRUG: Cabozantinib 40 MG oral once a day|DRUG: Pembrolizumab 200 mg IV every 3 weeks
Progression Free Survival, Six months progression free survival as defined by RECIST v1.1 measured from signed written consent to the date of first documented tumor progression using RECIST v1.1, or death due to any cause or 24 months after the end of study treatment., Up to 24 months
Overall Response Rate, Overall response defined by Response Evaluation Criteria in Solid Tumors (RECIST v.1.1 criteria)., Up to 24 months|Overall Survival, Overall survival will be defined as the time from signed written consent to the date of death or 24 months after the end of study treatment. A patient who has not died will be censored at the last known date of contact, Up to 24 months|Incidence of Emergent Adverse Events, Evaluate the safety and tolerability measured by incidence of adverse events and serious adverse events, deaths, and laboratory abnormalities as measured by Common Terminology Criteria for Adverse Events v.4.0, Up to 6 Months|Cervical Cancer Quality of Life, Quality of life as assessed by FACT Cx quality of life questionnaire. This frequency questionnaire is scaled from 0-4 with 0 being not at all and 4 being very much., Up to 6 Months
This study is a multi-center, single arm, open label trial to evaluate the efficacy and safety of Cabozantinib (XL184) plus Pembrolizumab in recurrent, persistent and/or metastatic cervical cancer with PD-L1 tumor positivity.